Login to Your Account

Biogen's BG-12 the Beneficiary?

Teva, Active Down Following Laquinimod Phase III Miss

By Tom Wall

Tuesday, August 2, 2011
Active Biotech AB stock plunged 53.5 percent and partner Teva Pharmaceutical Industries Ltd.'s shares took a 6.2 percent hit Monday following their announcement that oral multiple sclerosis (MS) drug laquinimod did not achieve its primary endpoint of reducing the annualized relapse rate (ARR) in the Phase III Bravo trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription